A Cohort Study to Evaluate the Real-World Utilization and Effectiveness of Bebtelovimab Compared to Paxlovid among Patients with Mild-to-Moderate COVID-19 Who Are at High Risk for Progressing to Severe Illness (J2X-MC-B003)

First published 09/02/2023

Last updated 17/06/2024

EU PAS number:

EUPAS50700

Study

Finalised

Documents

Study protocol

Initial protocol

LY3853113 J2X-MC-B003 RWE Protocol_Redacted

English (1.45 MB - PDF)View document

Updated protocol

LY3853113 J2X-MC-B003(a) RWE Protocol_Redacted

First published: 22/02/2024

English (1.31 MB - PDF)View document

Study results

Study report

LY3853113_J2X-MC-B003 Full Clinical Study Report_Redacted.pdf

English (2.71 MB - PDF)View document

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs